share_log

Codexis Reiterates 2024 Product Revenue Guidance $38M-$42M Excluding Revenue Related To PAXLOVID

Benzinga ·  May 3 05:40
Codexis Reiterates 2024 Product Revenue Guidance $38M-$42M Excluding Revenue Related To PAXLOVID
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment